Login to Your Account

Elan's Prialt Nears EU Approval; FDA Acceptance Should Follow

By Cormac Sheridan

Wednesday, November 24, 2004
For analysts eagerly anticipating developments with Antegren, Elan Corp. plc's multiple sclerosis drug, the news last week that Prialt, its first pain product, gained a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use was a pleasant sideshow. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription